Skip to main content
. 2021 Nov 1;81(18):2133–2137. doi: 10.1007/s40265-021-01626-7

Key clinical trials of regdanvimab (Celltrion Inc.)

Drug Indication Phase Status Location(s) Identifier
Regdanvimab COVID-19 infections II/III Completed Multinational NCT04602000, EudraCT2020-003369-20, CT-P59 3.2
Regdanvimab COVID-19 infections I Completed South Korea, Romania NCT04593641, EudraCT2020-003165-19, CT-P59 1.2
Regdanvimab COVID-19 infections I Completed South Korea NCT04525079, EudraCT2020-003065-19, CT-P59 1.1